Donald (“Don”) Abbey is Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs
Don assumed the role of Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs in January 2017, and previously served as Executive Vice President, Quality from May 2016 to January 2017.
Don has 30+ years of medical device and pharmaceutical industry experience. Prior to Dexcom, Don served in executive roles for Becton Dickinson (the acquirer of CareFusion which itself was spun off from Cardinal Health), including as Senior Vice President, Quality and Regulatory for Becton Dickinson, as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion, as Senior Vice President, Quality and Regulatory for CareFusion, and as Senior Vice President, Quality and Regulatory for Cardinal Health. Prior to 2007, Don held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare.
Don received a Bachelor of Science degree in Electrical Engineering from Washington State University and a Master of Business Administration from the University of Washington.
What is Donald Abbey's net worth?
The estimated net worth of Donald Abbey is at least $3.88 million as of April 4th, 2014. Mr. Abbey owns 28,143 shares of DexCom stock worth more than $3,884,015 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Abbey may own. Learn More about Donald Abbey's net worth.
How do I contact Donald Abbey?
Has Donald Abbey been buying or selling shares of DexCom?
Donald Abbey has not been actively trading shares of DexCom during the last quarter. Most recently, Donald Abbey sold 8,050 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $264.68, for a transaction totalling $2,130,674.00. Learn More on Donald Abbey's trading history.
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 40 times. They sold a total of 272,608 shares worth more than $35,590,010.39. The most recent insider tranaction occured on April, 15th when EVP Matthew Vincent Dolan sold 1,990 shares worth more than $274,241.90. Insiders at DexCom own 0.4% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 4/15/2024.
